CW February 2004
Volume 13Issue Number 2 February 2004 ISSN 10593802 Advantages for Cremaphor-Free Paclitaxel in Metastatic Breast CancerAmong women with metastatic breast cancer, the use of a non-Cremaphor based paclitaxel resulted in higher overall response rates, longer time to tumor progression, and fewer side effects, according to a presentation at the 26th Annual San Antonio Breast Cancer Symposium.
Go to Previous Page Go to Next Page Source & Additional Reading J. O?Shaughnessy, 26th Annual San Antonio Breast Cancer Symposium. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
